人生长激素治疗垂体性侏儒症的效力及安全性评价

New Drugs and Clinical Remedies 1997 Mar; 16(2):81-82 Evaluation of efficacy and safety of human growth-hormone in treating pituitary dwarfism

目的：对生物合成人生长激素（ｈＧＨ）治疗垂体性侏儒症的效力及安全性进行评价。方法：垂体性侏儒症１６例，男性，其中１２例年龄１１±ｓ３ａ（７～１５ａ），骨龄５±３ａ（２～１０ａ），４例年龄１８．０±１．４ａ（１６～１９ａ），骨龄１２．７±１．２ａ（１１～１４ａ）。给予ｈＧＨ，每日剂量０．１ＩＵ／（ｋｇ·ｄ），ｓｃ，６～１２ｍｏ。结果：骨龄≤１１ａ的年身高增长速率１１．０±１．２ｃｍ（Ｐ＜０．０５），骨龄＞１１ａ的年身高增长速率１０．０±１．０ｃｍ（Ｐ＜０．０５），副作用少，治疗期对血液生化无不良影响。结论：ｈＧＨ对垂体性侏儒症的治疗效果满意，安全性好。

AIM: To evaluate the efficacy and safety of human growth-hormone (hGH) in treating pituitary dwarfism. METHODS: Sixteen patients with pituritary dwarfs(M 12, age 11±s 3 a, bone age 5±3 a; M4, age 18.0±1.4 a, bone age 12.7±1.2 a) received hGH 0.1 IU/(kg·d), sc, dialy ×6-12 mo. RESULTS: Twelve patients with bone age <11 a had a height increase of 11.0±1.2 cm/a, while the other 4 patients with bone age >11 a had a height increase of 10.0±1.0 cm/a (P<0.05). No adverse reaction and harmful effects on blood biochemical change were found. CONCLUSION: hGH is effective and safe in treating pituitary dwarfism.